Prihlásiť sa Zaregistrujte sa zadarmo

Predpokladaný rast EPS Q/Q spoločnosti Navidea Biopharmaceuticals Inc

Aká je hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Navidea Biopharmaceuticals Inc?

Hodnota metriky Predpokladaný rast EPS Q/Q spoločnosti Navidea Biopharmaceuticals Inc je -72.73%

Aká je definícia metriky Predpokladaný rast EPS Q/Q?



Očakávaný rast EPS (Estimated quarterly EPS growth rate) z roka na rok je predpokladaný rast EPS spoločnosti za ďaľší kvartál v porovnaní s výsledkami z minulého kvartálu.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Predpokladaný rast EPS Q/Q spoločností v sektore Health Care sektor na NYSEMKT v porovnaní so spoločnosťou Navidea Biopharmaceuticals Inc

Čomu sa venuje spoločnosť Navidea Biopharmaceuticals Inc?

navidea biopharmaceuticals, inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. it operates through two segments, diagnostic substances and therapeutic development programs. the company develops manocept platform to target the cd206 mannose receptor expressed on activated macrophages. its cd206-targeted drug platform is applicable to a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (pet), imaging and topical gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. further, the company offers nav4694, a fluorine-18 labeled pet imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of alzheimer's disease and mild cognitive impairment. in addition, it is de

Firmy s metrikou predpokladaný rast eps q/q podobnou spoločnosti Navidea Biopharmaceuticals Inc